Welcome to our dedicated page for CRVN news (Ticker: CRVN), a resource for investors and traders seeking the latest updates and insights on CRVN stock.
Cerevance (CRVN) is described as a clinical-stage biopharmaceutical company developing cell type-specific therapies for neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders. The news associated with CRVN focuses on clinical trial readouts, mechanistic data, and scientific presentations related to its investigational pipeline and NETSseq discovery platform.
Company announcements highlight multiple clinical programs. For solengepras, an oral, non-dopaminergic GPR6 inhibitor in Phase 3 development for Parkinson’s disease, news items describe topline results from the Phase 2 ASCEND trial in early, untreated Parkinson’s disease and the design of the pivotal Phase 3 ARISE trial as adjunctive therapy to levodopa and other medications. These updates discuss patient-reported outcomes, motor and non-motor symptom measures, and safety findings.
News releases also cover CVN293, a highly selective investigational oral inhibitor of KCNK13 identified through the NETSseq platform. Cerevance reports Phase 1 data in healthy volunteers, including safety, tolerability, pharmacokinetics, and evidence of central nervous system exposure, and announces presentations at major meetings such as the American Academy of Neurology Annual Meeting and the Alzheimer’s Association International Conference.
Additional coverage describes posters and talks on the NETSseq platform itself and on CVN766, an orexin 1 receptor antagonist candidate for binge eating disorder and schizophrenia. Readers following CRVN news can expect updates on clinical trial milestones, conference presentations, early-stage data on investigational mechanisms, and the company’s characterization of its CNS-focused research strategy.
Cerevance (CRVN) has announced two upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto from July 27-31, 2025. The first presentation will discuss Phase 1 clinical trial results of CVN293, a KCNK13 inhibitor targeting neuroinflammation, which demonstrated good CNS exposure and tolerability. The second presentation will showcase findings from their proprietary NETSseq platform regarding astrocyte function in Alzheimer's disease.
The presentations are scheduled for July 28 and July 30, 2025, respectively, and will contribute to the company's ongoing research in neurodegenerative diseases.
Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation, at the American Academy of Neurology 2025 Annual Meeting. The randomized, double-blind, placebo-controlled study involved 72 healthy adults, evaluating single doses up to 1,000 mg and multiple doses up to 750 mg over 14 days.
Key findings showed that CVN293 was well-tolerated with:
- 100% participant completion rate
- No severe or dose-limiting adverse events
- Only mild treatment-related effects
- High levels of central nervous system exposure
- Generally dose-proportional plasma exposure
The company also presented data on their NETSseq platform and solengepras, a non-dopaminergic therapy in development for Parkinson's disease, including results from the Phase 2 ASCEND study in early, untreated Parkinson's patients.
Cerevance has announced topline results from its Phase 2 ASCEND trial of solengepras, an investigational monotherapy for early-stage Parkinson's disease. The oral, non-dopaminergic therapy showed potential benefits in functional and non-motor symptoms versus placebo.
Key findings include:
- Small, non-statistically significant improvement in motor symptoms (MDS-UPDRS Parts II+III)
- Trends in improvement observed in patient-reported measures including MDS-UPDRS Part I (-1.38, p=0.12) and Part II (-0.4, p=0.62)
- 100% patient completion rate with no serious adverse events related to the treatment
- Fewer adverse events related to non-motor symptoms in the treatment arm compared to placebo
The company's pivotal Phase 3 ARISE trial evaluating solengepras as adjunctive therapy in Parkinson's disease is ongoing, with topline data expected in first half of 2026.
Cerevance has announced upcoming presentations of clinical trial results at two major medical conferences in April 2025: the AD/PD™ 2025 in Vienna and the AAN Annual Meeting in San Diego. The key highlight will be the topline results from the Phase 2 ASCEND trial of solengepras (CVN424) as a monotherapy treatment for early-stage Parkinson's disease.
The company will also present first-time data from a Phase 1 trial of CVN293, a novel KCNK13 inhibitor targeting neuroinflammation in CNS diseases. Additional presentations will showcase their proprietary NETSseq platform's potential in identifying novel therapeutic targets for neurodegenerative diseases.